Intracellular killing of Brucella melitensis in human macrophages with microspheres-encapsulated gentamicin

Objectives: Treatment of human brucellosis demands antibiotic targeting into the mononuclearphagocytic system. The aim of this work was to prepare and characterize particulate carriers containing gentamicin and to study their interactions with phagocytic cells and bactericidal activity against intracellular Brucella melitensis. Methods: Different poly(lactide-co-glycolide) (PLGA)polymers with free carboxylic end-group wereusedto formulate micro- and nanoparticles containing gentamicin, by a water-oil-water solvent-evaporation technique. PLGA 502H and 75:25H microparticles were selected because they showed the highest gentamicin loadings as well as good physico-chemical properties and sustained release in vitro. Results: Gentamicin-containing microspheres of both polymers were successfully phagocytosed by infected THP-1 human monocytes, and immunocytochemistry studies revealed that the antibiotic reached Brucella-specific compartments. A dose of 30 mg of encapsulated gentamicin was able to reduce intracellular Brucella infection by 2.2 log. Conclusions: Altogether, these results suggest that 502H and 75:25H microspheres are suitable carriers for gentamicin targeting inside human macrophages and thus for brucellosis treatment

A Radiation Imaging Detector Made by Postprocessing a Standard CMOS Chip

An unpackaged microchip is used as the sensing element in a miniaturized gaseous proportional chamber. Thisletter reports on the fabrication and performance of a complete radiation imaging detector based on this principle. Our fabrication schemes are based on wafer-scale and chip-scale postprocessing.\ud Compared to hybrid-assembled gaseous detectors, our microsystem shows superior alignment precision and energy resolution, and offers the capability to unambiguously reconstruct 3-D radiation tracks on the spot.\u

Bases fisiológicas de la regeneración ósea II: el proceso de remodelado

El remodelado óseo es un proceso de reestructuración del hueso existente, que está en constante formación y reabsorción. Este fenómeno equilibrado permite, en condiciones normales, la renovación de un 5-10% del hueso total al año. A nivel microscópico el remodelado óseo se produce en las unidades básicas multicelulares, donde los osteoclastos reabsorben una cantidad determinada de hueso y los osteoblastos forman la matriz osteoide y la mineralizan para rellenar la cavidad previamente creada. En estas unidades hay osteoclastos, macrófagos, preosteoblastos y osteoblastos y están regidos por una serie de factores, tanto generales como locales, permitiendo el normal funcionamiento del hueso y el mantenimiento de la masa ósea. Cuando este proceso se desequilibra aparece la patología ósea, bien por exceso (osteopetrosis) o por defecto (osteoporosis). El propósito de este trabajo es realizar una revisión de los conocimientos actuales sobre los mecanismos bioquímicos y fisiológicos del proceso de remodelado óseo, resaltando de manera especial el papel de los factores reguladores del mismo, entre los que destacan los factores de crecimiento.Bone remodeling is the restructuring process of existing bone, which is in constant resorption and formation. Under normal conditions, this balanced process allows the renewal of 5 ' 10% of bone volume per year. At the microscopic level, bone remodeling is produced in basic multicellular units, where osteoclasts resorb a certain quantity of bone and osteoblasts form the osteoid matrix and mineralize it to fill the previously created cavity. These units contain osteoclasts, macrophages, preosteoblasts and osteoblasts, and are controlled by a series of factors, both general and local, allowing normal bone function and maintaining the bone mass. When this process becomes unbalanced then bone pathology appears, either in excess (osteopetrosis) or deficit (osteoporosis). The purpose of this study is to undertake a revision of current knowledge on the physiological and biological mechanisms of the bone remodeling process; highlighting the role played by the regulating factors, in particular that of the growth factors

Bases fisiológicas de la regeneración ósea I: histología y fisiología del tejido óseo

El hueso es el único tejido del organismo capaz de regenerarse, permitiendo la restitutio ad integrum tras el trauma. Cuando se produce una fractura, se coloca un implante osteointegrado o se realiza un injerto para aumentar el sustrato óseo antes de la inserción de implantes, lo que se pretende es la regeneración ósea, es decir, la formación de hueso nuevo que, tras un proceso de remodelado, sea idéntico al preexistente. El hueso es un tejido dinámico en constante formación y reabsorción. Este fenómeno equilibrado, denominado proceso de remodelado, permite la renovación de un 5-15 % del hueso total al año en condiciones normales (1). El remodelado óseo consiste en la reabsorción de una cantidad determinada de hueso llevada a cabo por los osteoclastos, así como la formación de la matriz osteoide por los osteoblastos y su posterior mineralización. Este fenómeno tiene lugar en pequeñas áreas de la cortical o de la superficie trabecular, llamadas 'unidades básicas de remodelado óseo'. La actuación terapéutica en los campos de la Traumatología y Ortopedia, Cirugía Oral y Maxilofacial e Implantología, se asienta sobre los principios biológicos de la regeneración ósea, en los que están implicados células, matriz extracelular y señales osteoinductivas. El objetivo de este trabajo es realizar una puesta al día de los conocimientos actuales sobre los mecanismos bioquímicos y fisiológicos de la regeneración ósea, resaltando de manera especial el papel que en ella juegan las células y las proteínas de la matriz ósea.Bone is the only body tissue capable of regeneration, allowing the restitutio ad integrum following trauma. In the event of a fracture or bone graft, new bone is formed, which following the remodeling process is identical to the pre-existing. Bone is a dynamic tissue in constant formation and resorption. This balanced phenomena, known as the remodeling process, allows the renovation of 5-15% of the total bone mass per year under normal conditions (1). Bone remodeling consists of the resorption of a certain amount of bone by osteoclasts, likewise the formation of osteoid matrix by osteoblasts, and its subsequent mineralization. This phenomenon occurs in small areas of the cortical bone or the trabecular surface, called 'Basic Multicellular Units' (BMU). Treatment in Traumatology, Orthopedics, Implantology, and Maxillofacial and Oral Surgery, is based on the biologic principals of bone regeneration, in which cells, extracellular matrix, and osteoinductive signals are involved. The aim of this paper is to provide an up date on current knowledge on the biochemical and physiological mechanisms of bone regeneration, paying particular attention to the role played by the cells and proteins of the bone matrix

La ciencia andaluza a golpe de ratón

El Sistema de Información Científica de Andalucía (SICA) es una ventana al conocimiento que se produce en nuestra comunidad autónoma. En 2010 ha comenzado el diseño de SICA2 que situará a esta plataforma en la vanguardia de la sistematización y la difusión de la investigació

Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method

OBJECTIVES: The aim of this work was to develop and validate an HPLC method for gentamicin quantification in different types of biological samples such as animal tissues and cellular material and also in pharmaceuticals. METHODS: Poly(lactide-co-glycolide) microparticles (MP) of gentamicin (PLGA 502H MP), THP-1 cells, and plasma and tissue samples of mice treated with the antibiotic either free or loaded into PLGA 502H MP were processed by a simple preparation procedure, subjected to chromatography on a reversed-phase column and measured by mass spectrometry detection. The developed method was compared with bioassay and fluorimetric assay methods previously used for gentamicin determination. RESULTS: The HPLC method was linear over the ranges 40-800 ng/mL and 0.1-100 microg/mL and showed good accuracy (average accuracy < 5.59%) and reproducibility (CV < 6.13%). Encapsulation of gentamicin in PLGA 502H MP was determined by the three methods. Good correlation was observed between bioassay (reference method) and HPLC. Extra- and intracellular in vitro antibiotic accumulation was determined by bioassay and chromatography. Both methods gave similar extracellular concentrations but the HPLC-MS technique demonstrated an improved accuracy (5.59% versus 14%) and precision (6.13% versus 15%) compared with bioassay. However, only the HPLC-MS method was sensitive enough to detect the drug, intracellularly and in tissues. CONCLUSIONS: All these data favour the use of chromatography-mass spectrometry as a versatile technique not only suitable for gentamicin quantification loaded in drug delivery systems, but also sensitive and specific enough for in vivo and intracellular studies

Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems.

Edelfosine is a synthetic alkyl ether phospholipid that represents a promising class of antitumor agents. However, analytical methods to measure these type compounds are scarce. The lack of a reliable methodology to quantify edelfosine is a major problem in ongoing and scheduled preclinical and clinical trials with this drug. We evaluated the applicability of high-performance liquid chromatography–mass spectrometry to determine edelfosine in biological samples and polymeric delivery systems. Sample pre-treatment involved polymer precipitation or cell lysis with methanol. HPLC separation was performed on an Alltima RPC18 narrow-bore column and edelfosine quantification was done by electrospray ionization mass spectrometry (ESI-MS) using positive ion mode and selected ion monitoring. Assays were linear in the tested range of 0.3–10 μg/ml. The limit of quantification was 0.3 ng/sample in both matrices, namely biological samples and polymeric delivery systems. The interassay precision ranging from 0.79 to 1.49%, with relative errors of −6.7 and 12.8%. Mean extraction recovery was 95.6%. HPLC–ESI-MS is a reliable system for edelfosine analysis and quantification in samples from different sources, combining advantages of full automation (rapidity, ease of use, no need of extensive extraction procedures) with high analytical performance and throughput

Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres.

The aim of the work was to develop biodegradable microspheres for controlled delivery of the somatostatin analogue vapreotide and maintenance of sustained plasma levels over 2–4 weeks after a single injection in rats. Vapreotide was microencapsulated into end-group capped and uncapped low molecular weight poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) by spray-drying and coacervation. Microspheres were prepared from single and blended (1:1) polymer types. The microparticles were characterized for peptide loading, in vitro release and pharmocokinetics in rats. Spray-drying and coacervation produced microspheres in the size range of 1–15 and 10–70 μm, respectively, and with encapsulation efficiencies varying between 46% and 87%. In vitro release of vapreotide followed a regular pattern and lasted more than 4 weeks, time at which 40–80% of the total dose were released. Microspheres made of 14-kDa end-group uncapped PLGA50:50 or 1:1 blends of this polymer with 35 kDa end-group uncapped PLGA50:50 gave the best release profiles and yielded the most sustained plasma levels above a pre-defined 1 ng/ml over approximately 14 days. In vitro/in vivo correlation analyses showed for several microsphere formulations a linear correlation between the mean residence time in vivo and the mean dissolution time (r=0.958) and also between the amount released between 6 h and 14 days and the AUC6h–14d (r=0.932). For several other parameters or time periods, no in vitro/in vivo correlation was found. This study demonstrates that controlled release of the vapreotide is possible in vivo for a duration of a least 2 weeks when administered i.m. to rats. These results constitute a step forward towards a twice-a-month or once-a-month microsphere-formulation for the treatment of acromegaly and neuroendocrine tumors